Cordis goes back to PRISON
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis' drug-eluting Cypher stent is associated with an in-stent restenosis rate of 7% compared to 36% with the Bx Velocity stent in the 200-patient randomized PRISON II trial comparing the stents in patients with chronic total occlusions, according to principal investigator Maarten Suttorp, MD, PhD, St. Antonius Hospital, The Netherlands. Cypher also had a lower target lesion revascularization rate than the bare-metal stent (4% vs. 19%) and a lower MACE rate (4% vs. 20%)...
You may also be interested in...
Randomized Trials Sought To Show DES Benefits For Chronic Total Occlusions
Despite growing data on the use of drug-eluting stents in the treatment of chronic total occlusions, more trials are needed to establish their benefit, experts say
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.